Most Read Articles
Pearl Toh, 03 Jul 2020
After treatment with fremanezumab, a difficult-to-treat patient population with treatment-resistant episodic or chronic migraine saw sustained benefits across a broad range of measures, according to multiple analyses of the FOCUS study released during the AHS 2020 Virtual Meeting.
Pearl Toh, 24 Jun 2020
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.
Elvira Manzano, 24 Oct 2018
New evidence showed that a high-fat, low-carbohydrate ketogenic diet could help improve symptoms in patients with Parkinson's disease (PD), so did a low-fat, high-carbohydrate diet.
Pearl Toh, 01 Jul 2020
The CGRP* receptor blocker erenumab shows sustained efficacy in reducing migraine frequency over 2 years in a difficult-to-treat patient population with episodic migraine who had failed 2–4 prior preventive treatments, an interim analysis of the LIBERTY** open-label extension study shows.

Cerebrospinal fluid markers may help assess neurodegeneration

27 Dec 2019
Many scientists believe that amyloids are key to the disease's effect on neurons

While cerebrospinal fluid (CSF) neurofilament light (NfL) levels indicate general and overall neurodegeneration, total tau (T-tau) and neurogranin (Ng) concentrations may be markers for neuronal response to amyloid pathology and neurodegeneration specific to Alzheimer’s disease (AD), a recent study has shown.

The study included 777 community-based adults (aged 50–95 years; 57.0 percent male) whose CSF samples were subjected to electrochemiluminescence and enzyme-linked immunosorbent assays for the measurement of NfL, Ng and T-tau levels.

Eighty-three (10.7 percent) participants were diagnosed with mild cognitive impairment (MCI), while seven (0.9 percent) had dementia. The median concentrations of NfL and T-tau levels increased with disease severity; no such effect was reported for Ng.

Multivariable analysis adjusted for covariates found that a diagnosis of MCI was associated only with elevated NfL levels, and not with high concentrations of T-tau or Ng. Stratifying by cognitive status, the correlations between cognition and each of the CSF markers were stronger in those with MCI or dementia.

Moreover, both gait speed and scores in the Charlson comorbidity index were more strongly associated with CSF T-tau and Ng in patients who were positive for amyloid pathology.

“As CSF NfL, T-tau and Ng move toward use in the clinic or for clinical trials as markers of disease progression and neurodegeneration, it is critical to better understand what these markers are measuring,” said researchers.

“Furthermore, with a move to clinical use, the development of reference ranges is needed,” they added.

Editor's Recommendations
Most Read Articles
Pearl Toh, 03 Jul 2020
After treatment with fremanezumab, a difficult-to-treat patient population with treatment-resistant episodic or chronic migraine saw sustained benefits across a broad range of measures, according to multiple analyses of the FOCUS study released during the AHS 2020 Virtual Meeting.
Pearl Toh, 24 Jun 2020
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.
Elvira Manzano, 24 Oct 2018
New evidence showed that a high-fat, low-carbohydrate ketogenic diet could help improve symptoms in patients with Parkinson's disease (PD), so did a low-fat, high-carbohydrate diet.
Pearl Toh, 01 Jul 2020
The CGRP* receptor blocker erenumab shows sustained efficacy in reducing migraine frequency over 2 years in a difficult-to-treat patient population with episodic migraine who had failed 2–4 prior preventive treatments, an interim analysis of the LIBERTY** open-label extension study shows.